Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Research Report 2026(Status and Outlook)
Small nucleic acid drugs are short in length and have a base of less than 30 nt. They mainly act on mRNA in cells through the principle of complementary base pairing to regulate protein expression, thereby achieving therapeutic effects. It can be further divided into single-stranded antisense oligonucleotide ASO, and double-stranded nucleotide siRNA.The main market drivers of antisense oligonucleotide (ASO) drugs and siRNA drugs include the following:1. Technological breakthrough: the leap from laboratory to clinicTechnological evolution of ASO drugsChemical modification and delivery system optimization: The first generation of ASO drugs were limited by poor stability and high immunogenicity. The third generation of ASO significantly improved the resistance to nucleases and pharmacokinetic properties through thiophosphate backbone modification, glycosylation modification and other technologies. For example, Ionis' Eplontersen uses ligand coupling technology to achieve subcutaneous administration once a month, which greatly improves patient compliance.Indication expansion: ASO drugs extend from genetic diseases (such as Duchenne muscular dystrophy) to tumors and metabolic diseases. Geron's Imetelstat was approved as the first telomerase inhibitor, providing a new treatment for myelodysplastic syndrome.Technological revolution of siRNA drugsDelivery system breakthrough: In 2014, the GalNAc ligand technology came into being, solving the problem of liver targeting and promoting Alnylam's Onpattro (approved in 2018) to become the first siRNA drug. Current research focuses on multi-organ delivery, such as Alnylam's mivelsiran (Phase II for cerebral amyloid angiopathy) and Arrowhead's ARO-RAGE (Phase I for asthma), which achieve cross-blood-brain barrier targeting through lipid nanoparticles (LNP) or antibody coupling.Advantages of long-term efficacy and reversibility: siRNA drugs such as Inclisiran (lipid-lowering) can be administered once every six months, and the effect is reversible, avoiding the permanent risk of gene editing.2. Policy support: Catalyst for the global innovative drug ecosystemRegulatory approval accelerationThe FDA accelerates the approval of small nucleic acid drugs through mechanisms such as "fast track" and "breakthrough therapy". For example, Eplontersen took only 3 years from clinical to approval, which is far lower than the 10-year cycle of traditional drugs.China's "14th Five-Year Plan for the Development of the Pharmaceutical Industry" clearly supports the development of new delivery systems, optimizes the review process, and promotes ASO/siRNA drugs into clinical trials.Medical insurance coverage and payment innovationEuropean and American medical insurance explores the "pay-by-efficacy" model for high-priced small nucleic acid drugs (such as Onpattro, which costs about $450,000 per year) to reduce the burden on patients.China is incorporating drugs for rare diseases into medical insurance negotiations. The ASO drug Spinraza (nusinersen) has been negotiated to reduce its price, and its accessibility has been improved.3. Market demand: a blue ocean with unmet clinical needsGenetic diseases and rare diseasesASO drugs dominate the field of spinal muscular atrophy (SMA), with global sales of Spinraza exceeding US$2 billion. siRNA drugs such as Amvuttra (transthyretin amyloidosis) fill the gap in the treatment of genetic diseases.There are more than 300 million patients with rare diseases worldwide, but approved drugs only cover 5%, and the market potential is huge.Expansion of chronic and metabolic diseasesThe siRNA drug Inclisiran has expanded its indications from familial hypercholesterolemia to atherosclerotic cardiovascular disease, and the patient population has expanded 10 times.In the field of metabolic-associated fatty hepatitis (MASH), Alnylam's Lundquist and other siRNA drugs have entered Phase III clinical trials, and the market size is expected to exceed US$35 billion in 2030.IV. Capital investment: the "fuel" for innovative drug research and developmentVenture capital and IPO are activeIn 2023, there will be 31 transactions in the global small nucleic acid field, with a total amount of US$8.496 billion (up 371% year-on-year). China Jingyin Pharmaceutical completed nearly US$50 million in B2 round financing to accelerate the development of cardiovascular siRNA pipeline.In 2024, Boehringer Ingelheim and Ribo Bio reached a US$2 billion cooperation to develop siRNA drugs for MASH.The layout of multinational pharmaceutical companies is acceleratingAstraZeneca introduced Ionis's Eplontersen for US$3.585 billion to expand the field of heart failure; Novartis consolidated the cardiovascular market through Leqvio (lipid-lowering siRNA).In 2025, GSK acquired Boston Pharmaceuticals' FGF21 siRNA project for US$1.2 billion, betting on metabolic diseases.5. Competition landscape: Evolution from "unipolar" to "multipolar"Monopoly and breakthroughs of international giantsIonis (ASO) and Alnylam (siRNA) occupy the main global market share, but newcomers such as Arrowhead and Dicerna challenge the leading position through differentiated technologies (such as multi-organ delivery).Eli Lilly cooperates with Alnylam to develop siRNA drugs for Alzheimer's disease, using its delivery technology to break through the blood-brain barrier.The rise of Chinese companiesDomestic ASO field: Ruibo Bio and Yuekang Pharmaceuticals advance clinical pipelines through cooperative development, but no self-developed products have been launched.siRNA field: Many drugs of Shengyin Bio and Bowang Pharmaceutical have entered Phase I, targeting common diseases such as hypertension and hyperlipidemia, filling the domestic gap.6. Challenges and future trendsTechnical bottlenecks to be broken throughThe off-target effects and immunogenicity of ASO drugs still need to be optimized; the kidney and lung delivery efficiency of siRNA is low, which limits the expansion of indications.Competitive pressure from gene editing technologies (such as CRISPR): Verve Therapeutics' PCSK9 gene editing therapy has entered clinical trials and may replace part of the siRNA market.Driven by policy support and capital, the growth rate of the Chinese market will be higher than the global average, and ASO/siRNA drugs are expected to become the core track of the "new infrastructure" of biomedicine.The market explosion of ASO and siRNA drugs is the result of the resonance of technological breakthroughs, policy dividends, capital catalysis and unmet needs. In the future, with the innovation of delivery systems and the expansion of multiple indications, small nucleic acid drugs will move from "niche genetic diseases" to "mass chronic diseases", reshaping the global pharmaceutical landscape.
The global Antisense oligonucleotides (ASO) Drug and siRNA Drug market size was estimated at USD 3192.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 23.00% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Antisense oligonucleotides (ASO) Drug and siRNA Drug market.
Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Alnylam
Ionis
Biogen
Novartis
Sarepta Therapeutics
Therapeutics
Akcea
WAVElife
ProQR
Exicure
Secarna
AstraZeneca
The WhiteOak Group, Inc.
Dicerna
Silence
Arrowhead
Miragen Therapeutics
Genzyme
Quark Pharmaceuticals
Sylentis
Avidity Biosciences
Novo Nordisk
Sirnaomics
Market Segmentation (by Type)
Antisense Oligonucleotides (ASO) Drug
siRNA Drug
Market Segmentation (by Application)
Single Gene Rare Disease
Protein Deposition Disease
Chronic Liver Disease
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market
Overview of the regional outlook of the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Antisense oligonucleotides (ASO) Drug and siRNA Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Antisense oligonucleotides (ASO) Drug and siRNA Drug market size was estimated at USD 3192.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 23.00% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Antisense oligonucleotides (ASO) Drug and siRNA Drug market.
Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Alnylam
Ionis
Biogen
Novartis
Sarepta Therapeutics
Therapeutics
Akcea
WAVElife
ProQR
Exicure
Secarna
AstraZeneca
The WhiteOak Group, Inc.
Dicerna
Silence
Arrowhead
Miragen Therapeutics
Genzyme
Quark Pharmaceuticals
Sylentis
Avidity Biosciences
Novo Nordisk
Sirnaomics
Market Segmentation (by Type)
Antisense Oligonucleotides (ASO) Drug
siRNA Drug
Market Segmentation (by Application)
Single Gene Rare Disease
Protein Deposition Disease
Chronic Liver Disease
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market
Overview of the regional outlook of the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Antisense oligonucleotides (ASO) Drug and siRNA Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Antisense oligonucleotides (ASO) Drug and siRNA Drug
1.2 Key Market Segments
1.2.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Type
1.2.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Life Cycle
3.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Manufacturers (2020-2025)
3.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Manufacturers (2020-2025)
3.5 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Competitive Situation and Trends
3.8.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Concentration Rate
3.8.2 Global 5 and 10 Largest Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG INDUSTRY CHAIN ANALYSIS
4.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Antisense oligonucleotides (ASO) Drug and siRNA Drug Market
5.7 ESG Ratings of Leading Companies
6 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2020-2025)
6.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (2020-2025)
6.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Type (2020-2025)
7 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Sales by Application (2020-2025)
7.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) by Application (2020-2025)
7.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Growth Rate by Application (2020-2025)
8 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET SALES BY REGION
8.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
8.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
8.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region
8.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.3 North America
8.3.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country
8.3.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country
8.4.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
8.5.2 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country
8.6.2 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
8.7.2 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET PRODUCTION BY REGION
9.1 Global Production of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Region(2020-2025)
9.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2020-2025)
9.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production
9.4.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Growth Rate (2020-2025)
9.4.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production
9.5.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Growth Rate (2020-2025)
9.5.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (2020-2025)
9.6.1 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Growth Rate (2020-2025)
9.6.2 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (2020-2025)
9.7.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Growth Rate (2020-2025)
9.7.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Alnylam
10.1.1 Alnylam Basic Information
10.1.2 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.1.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.1.4 Alnylam Business Overview
10.1.5 Alnylam SWOT Analysis
10.1.6 Alnylam Recent Developments
10.2 Ionis
10.2.1 Ionis Basic Information
10.2.2 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.2.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.2.4 Ionis Business Overview
10.2.5 Ionis SWOT Analysis
10.2.6 Ionis Recent Developments
10.3 Biogen
10.3.1 Biogen Basic Information
10.3.2 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.3.4 Biogen Business Overview
10.3.5 Biogen SWOT Analysis
10.3.6 Biogen Recent Developments
10.4 Novartis
10.4.1 Novartis Basic Information
10.4.2 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.4.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.4.4 Novartis Business Overview
10.4.5 Novartis Recent Developments
10.5 Sarepta Therapeutics
10.5.1 Sarepta Therapeutics Basic Information
10.5.2 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.5.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.5.4 Sarepta Therapeutics Business Overview
10.5.5 Sarepta Therapeutics Recent Developments
10.6 Therapeutics
10.6.1 Therapeutics Basic Information
10.6.2 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.6.4 Therapeutics Business Overview
10.6.5 Therapeutics Recent Developments
10.7 Akcea
10.7.1 Akcea Basic Information
10.7.2 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.7.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.7.4 Akcea Business Overview
10.7.5 Akcea Recent Developments
10.8 WAVElife
10.8.1 WAVElife Basic Information
10.8.2 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.8.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.8.4 WAVElife Business Overview
10.8.5 WAVElife Recent Developments
10.9 ProQR
10.9.1 ProQR Basic Information
10.9.2 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.9.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.9.4 ProQR Business Overview
10.9.5 ProQR Recent Developments
10.10 Exicure
10.10.1 Exicure Basic Information
10.10.2 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.10.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.10.4 Exicure Business Overview
10.10.5 Exicure Recent Developments
10.11 Secarna
10.11.1 Secarna Basic Information
10.11.2 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.11.4 Secarna Business Overview
10.11.5 Secarna Recent Developments
10.12 AstraZeneca
10.12.1 AstraZeneca Basic Information
10.12.2 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.12.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.12.4 AstraZeneca Business Overview
10.12.5 AstraZeneca Recent Developments
10.13 The WhiteOak Group, Inc.
10.13.1 The WhiteOak Group, Inc. Basic Information
10.13.2 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.13.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.13.4 The WhiteOak Group, Inc. Business Overview
10.13.5 The WhiteOak Group, Inc. Recent Developments
10.14 Dicerna
10.14.1 Dicerna Basic Information
10.14.2 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.14.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.14.4 Dicerna Business Overview
10.14.5 Dicerna Recent Developments
10.15 Silence
10.15.1 Silence Basic Information
10.15.2 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.15.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.15.4 Silence Business Overview
10.15.5 Silence Recent Developments
10.16 Arrowhead
10.16.1 Arrowhead Basic Information
10.16.2 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.16.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.16.4 Arrowhead Business Overview
10.16.5 Arrowhead Recent Developments
10.17 Miragen Therapeutics
10.17.1 Miragen Therapeutics Basic Information
10.17.2 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.17.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.17.4 Miragen Therapeutics Business Overview
10.17.5 Miragen Therapeutics Recent Developments
10.18 Genzyme
10.18.1 Genzyme Basic Information
10.18.2 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.18.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.18.4 Genzyme Business Overview
10.18.5 Genzyme Recent Developments
10.19 Quark Pharmaceuticals
10.19.1 Quark Pharmaceuticals Basic Information
10.19.2 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.19.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.19.4 Quark Pharmaceuticals Business Overview
10.19.5 Quark Pharmaceuticals Recent Developments
10.20 Sylentis
10.20.1 Sylentis Basic Information
10.20.2 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.20.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.20.4 Sylentis Business Overview
10.20.5 Sylentis Recent Developments
10.21 Avidity Biosciences
10.21.1 Avidity Biosciences Basic Information
10.21.2 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.21.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.21.4 Avidity Biosciences Business Overview
10.21.5 Avidity Biosciences Recent Developments
10.22 Novo Nordisk
10.22.1 Novo Nordisk Basic Information
10.22.2 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.22.3 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.22.4 Novo Nordisk Business Overview
10.22.5 Novo Nordisk Recent Developments
10.23 Sirnaomics
10.23.1 Sirnaomics Basic Information
10.23.2 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.23.3 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.23.4 Sirnaomics Business Overview
10.23.5 Sirnaomics Recent Developments
11 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET FORECAST BY REGION
11.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast
11.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country
11.2.3 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Region
11.2.4 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2026-2035)
12.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2026-2035)
12.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Forecast by Application (2026-2035)
12.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) Forecast by Application
12.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Antisense oligonucleotides (ASO) Drug and siRNA Drug
1.2 Key Market Segments
1.2.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Type
1.2.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Life Cycle
3.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Manufacturers (2020-2025)
3.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Manufacturers (2020-2025)
3.5 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Competitive Situation and Trends
3.8.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Concentration Rate
3.8.2 Global 5 and 10 Largest Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG INDUSTRY CHAIN ANALYSIS
4.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Antisense oligonucleotides (ASO) Drug and siRNA Drug Market
5.7 ESG Ratings of Leading Companies
6 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2020-2025)
6.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (2020-2025)
6.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Type (2020-2025)
7 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Sales by Application (2020-2025)
7.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) by Application (2020-2025)
7.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Growth Rate by Application (2020-2025)
8 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET SALES BY REGION
8.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
8.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
8.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region
8.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.3 North America
8.3.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country
8.3.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country
8.4.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
8.5.2 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country
8.6.2 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region
8.7.2 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET PRODUCTION BY REGION
9.1 Global Production of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Region(2020-2025)
9.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2020-2025)
9.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production
9.4.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Growth Rate (2020-2025)
9.4.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production
9.5.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Growth Rate (2020-2025)
9.5.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (2020-2025)
9.6.1 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Growth Rate (2020-2025)
9.6.2 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (2020-2025)
9.7.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Growth Rate (2020-2025)
9.7.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Alnylam
10.1.1 Alnylam Basic Information
10.1.2 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.1.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.1.4 Alnylam Business Overview
10.1.5 Alnylam SWOT Analysis
10.1.6 Alnylam Recent Developments
10.2 Ionis
10.2.1 Ionis Basic Information
10.2.2 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.2.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.2.4 Ionis Business Overview
10.2.5 Ionis SWOT Analysis
10.2.6 Ionis Recent Developments
10.3 Biogen
10.3.1 Biogen Basic Information
10.3.2 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.3.4 Biogen Business Overview
10.3.5 Biogen SWOT Analysis
10.3.6 Biogen Recent Developments
10.4 Novartis
10.4.1 Novartis Basic Information
10.4.2 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.4.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.4.4 Novartis Business Overview
10.4.5 Novartis Recent Developments
10.5 Sarepta Therapeutics
10.5.1 Sarepta Therapeutics Basic Information
10.5.2 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.5.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.5.4 Sarepta Therapeutics Business Overview
10.5.5 Sarepta Therapeutics Recent Developments
10.6 Therapeutics
10.6.1 Therapeutics Basic Information
10.6.2 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.6.4 Therapeutics Business Overview
10.6.5 Therapeutics Recent Developments
10.7 Akcea
10.7.1 Akcea Basic Information
10.7.2 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.7.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.7.4 Akcea Business Overview
10.7.5 Akcea Recent Developments
10.8 WAVElife
10.8.1 WAVElife Basic Information
10.8.2 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.8.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.8.4 WAVElife Business Overview
10.8.5 WAVElife Recent Developments
10.9 ProQR
10.9.1 ProQR Basic Information
10.9.2 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.9.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.9.4 ProQR Business Overview
10.9.5 ProQR Recent Developments
10.10 Exicure
10.10.1 Exicure Basic Information
10.10.2 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.10.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.10.4 Exicure Business Overview
10.10.5 Exicure Recent Developments
10.11 Secarna
10.11.1 Secarna Basic Information
10.11.2 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.11.4 Secarna Business Overview
10.11.5 Secarna Recent Developments
10.12 AstraZeneca
10.12.1 AstraZeneca Basic Information
10.12.2 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.12.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.12.4 AstraZeneca Business Overview
10.12.5 AstraZeneca Recent Developments
10.13 The WhiteOak Group, Inc.
10.13.1 The WhiteOak Group, Inc. Basic Information
10.13.2 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.13.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.13.4 The WhiteOak Group, Inc. Business Overview
10.13.5 The WhiteOak Group, Inc. Recent Developments
10.14 Dicerna
10.14.1 Dicerna Basic Information
10.14.2 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.14.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.14.4 Dicerna Business Overview
10.14.5 Dicerna Recent Developments
10.15 Silence
10.15.1 Silence Basic Information
10.15.2 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.15.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.15.4 Silence Business Overview
10.15.5 Silence Recent Developments
10.16 Arrowhead
10.16.1 Arrowhead Basic Information
10.16.2 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.16.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.16.4 Arrowhead Business Overview
10.16.5 Arrowhead Recent Developments
10.17 Miragen Therapeutics
10.17.1 Miragen Therapeutics Basic Information
10.17.2 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.17.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.17.4 Miragen Therapeutics Business Overview
10.17.5 Miragen Therapeutics Recent Developments
10.18 Genzyme
10.18.1 Genzyme Basic Information
10.18.2 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.18.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.18.4 Genzyme Business Overview
10.18.5 Genzyme Recent Developments
10.19 Quark Pharmaceuticals
10.19.1 Quark Pharmaceuticals Basic Information
10.19.2 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.19.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.19.4 Quark Pharmaceuticals Business Overview
10.19.5 Quark Pharmaceuticals Recent Developments
10.20 Sylentis
10.20.1 Sylentis Basic Information
10.20.2 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.20.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.20.4 Sylentis Business Overview
10.20.5 Sylentis Recent Developments
10.21 Avidity Biosciences
10.21.1 Avidity Biosciences Basic Information
10.21.2 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.21.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.21.4 Avidity Biosciences Business Overview
10.21.5 Avidity Biosciences Recent Developments
10.22 Novo Nordisk
10.22.1 Novo Nordisk Basic Information
10.22.2 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.22.3 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.22.4 Novo Nordisk Business Overview
10.22.5 Novo Nordisk Recent Developments
10.23 Sirnaomics
10.23.1 Sirnaomics Basic Information
10.23.2 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
10.23.3 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Market Performance
10.23.4 Sirnaomics Business Overview
10.23.5 Sirnaomics Recent Developments
11 ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG AND SIRNA DRUG MARKET FORECAST BY REGION
11.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast
11.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country
11.2.3 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Region
11.2.4 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2026-2035)
12.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2026-2035)
12.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Forecast by Application (2026-2035)
12.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) Forecast by Application
12.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (M USD)
Table 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
Table 5. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Comparison by Region (M USD)
Table 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug as of 2025)
Table 11. Global Market Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (K MT)
Table 27. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (M USD)
Table 28. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) by Type (2020-2025)
Table 29. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2020-2025)
Table 30. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) by Type (2020-2025)
Table 31. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type (2020-2025)
Table 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price (USD/KG) by Type (2020-2025)
Table 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) by Application
Table 34. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
Table 35. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2020-2025) & (K MT)
Table 36. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2020-2025)
Table 37. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application (2020-2025) & (M USD)
Table 38. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application (2020-2025)
Table 39. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Growth Rate by Application (2020-2025)
Table 40. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2020-2025) & (K MT)
Table 41. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2020-2025)
Table 42. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025) & (M USD)
Table 43. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025)
Table 44. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2020-2025) & (K MT)
Table 45. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2020-2025) & (K MT)
Table 47. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025) & (M USD)
Table 50. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2020-2025) & (K MT)
Table 51. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025) & (M USD)
Table 54. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) by Region(2020-2025)
Table 55. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2020-2025)
Table 57. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Alnylam Basic Information
Table 63. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 64. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Alnylam Business Overview
Table 66. Alnylam SWOT Analysis
Table 67. Alnylam Recent Developments
Table 68. Ionis Basic Information
Table 69. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 70. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Ionis Business Overview
Table 72. Ionis SWOT Analysis
Table 73. Ionis Recent Developments
Table 74. Biogen Basic Information
Table 75. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 76. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Biogen Business Overview
Table 78. Biogen SWOT Analysis
Table 79. Biogen Recent Developments
Table 80. Novartis Basic Information
Table 81. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 82. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Novartis Business Overview
Table 84. Novartis Recent Developments
Table 85. Sarepta Therapeutics Basic Information
Table 86. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 87. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Sarepta Therapeutics Business Overview
Table 89. Sarepta Therapeutics Recent Developments
Table 90. Therapeutics Basic Information
Table 91. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 92. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Therapeutics Business Overview
Table 94. Therapeutics Recent Developments
Table 95. Akcea Basic Information
Table 96. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 97. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Akcea Business Overview
Table 99. Akcea Recent Developments
Table 100. WAVElife Basic Information
Table 101. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 102. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. WAVElife Business Overview
Table 104. WAVElife Recent Developments
Table 105. ProQR Basic Information
Table 106. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 107. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. ProQR Business Overview
Table 109. ProQR Recent Developments
Table 110. Exicure Basic Information
Table 111. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 112. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Exicure Business Overview
Table 114. Exicure Recent Developments
Table 115. Secarna Basic Information
Table 116. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 117. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Secarna Business Overview
Table 119. Secarna Recent Developments
Table 120. AstraZeneca Basic Information
Table 121. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 122. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. AstraZeneca Business Overview
Table 124. AstraZeneca Recent Developments
Table 125. The WhiteOak Group, Inc. Basic Information
Table 126. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 127. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. The WhiteOak Group, Inc. Business Overview
Table 129. The WhiteOak Group, Inc. Recent Developments
Table 130. Dicerna Basic Information
Table 131. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 132. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Dicerna Business Overview
Table 134. Dicerna Recent Developments
Table 135. Silence Basic Information
Table 136. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 137. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Silence Business Overview
Table 139. Silence Recent Developments
Table 140. Arrowhead Basic Information
Table 141. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 142. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Arrowhead Business Overview
Table 144. Arrowhead Recent Developments
Table 145. Miragen Therapeutics Basic Information
Table 146. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 147. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. Miragen Therapeutics Business Overview
Table 149. Miragen Therapeutics Recent Developments
Table 150. Genzyme Basic Information
Table 151. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 152. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 153. Genzyme Business Overview
Table 154. Genzyme Recent Developments
Table 155. Quark Pharmaceuticals Basic Information
Table 156. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 157. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 158. Quark Pharmaceuticals Business Overview
Table 159. Quark Pharmaceuticals Recent Developments
Table 160. Sylentis Basic Information
Table 161. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 162. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 163. Sylentis Business Overview
Table 164. Sylentis Recent Developments
Table 165. Avidity Biosciences Basic Information
Table 166. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 167. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 168. Avidity Biosciences Business Overview
Table 169. Avidity Biosciences Recent Developments
Table 170. Novo Nordisk Basic Information
Table 171. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 172. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 173. Novo Nordisk Business Overview
Table 174. Novo Nordisk Recent Developments
Table 175. Sirnaomics Basic Information
Table 176. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 177. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 178. Sirnaomics Business Overview
Table 179. Sirnaomics Recent Developments
Table 180. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Region (2026-2035) & (K MT)
Table 181. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Region (2026-2035) & (M USD)
Table 182. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 183. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 184. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 185. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 186. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Region (2026-2035) & (K MT)
Table 187. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Region (2026-2035) & (M USD)
Table 188. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 189. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 190. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Country (2026-2035) & (Units)
Table 191. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 192. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Type (2026-2035) & (K MT)
Table 193. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Type (2026-2035) & (M USD)
Table 194. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price Forecast by Type (2026-2035) & (USD/KG)
Table 195. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) Forecast by Application (2026-2035)
Table 196. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (M USD)
Table 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
Table 5. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Comparison by Region (M USD)
Table 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug as of 2025)
Table 11. Global Market Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (K MT)
Table 27. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (M USD)
Table 28. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) by Type (2020-2025)
Table 29. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2020-2025)
Table 30. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) by Type (2020-2025)
Table 31. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type (2020-2025)
Table 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price (USD/KG) by Type (2020-2025)
Table 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) by Application
Table 34. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
Table 35. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2020-2025) & (K MT)
Table 36. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2020-2025)
Table 37. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application (2020-2025) & (M USD)
Table 38. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application (2020-2025)
Table 39. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Growth Rate by Application (2020-2025)
Table 40. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2020-2025) & (K MT)
Table 41. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2020-2025)
Table 42. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025) & (M USD)
Table 43. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025)
Table 44. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2020-2025) & (K MT)
Table 45. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2020-2025) & (K MT)
Table 47. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025) & (M USD)
Table 50. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2020-2025) & (K MT)
Table 51. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025) & (M USD)
Table 54. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) by Region(2020-2025)
Table 55. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2020-2025)
Table 57. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Alnylam Basic Information
Table 63. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 64. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Alnylam Business Overview
Table 66. Alnylam SWOT Analysis
Table 67. Alnylam Recent Developments
Table 68. Ionis Basic Information
Table 69. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 70. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Ionis Business Overview
Table 72. Ionis SWOT Analysis
Table 73. Ionis Recent Developments
Table 74. Biogen Basic Information
Table 75. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 76. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Biogen Business Overview
Table 78. Biogen SWOT Analysis
Table 79. Biogen Recent Developments
Table 80. Novartis Basic Information
Table 81. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 82. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Novartis Business Overview
Table 84. Novartis Recent Developments
Table 85. Sarepta Therapeutics Basic Information
Table 86. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 87. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Sarepta Therapeutics Business Overview
Table 89. Sarepta Therapeutics Recent Developments
Table 90. Therapeutics Basic Information
Table 91. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 92. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Therapeutics Business Overview
Table 94. Therapeutics Recent Developments
Table 95. Akcea Basic Information
Table 96. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 97. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Akcea Business Overview
Table 99. Akcea Recent Developments
Table 100. WAVElife Basic Information
Table 101. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 102. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. WAVElife Business Overview
Table 104. WAVElife Recent Developments
Table 105. ProQR Basic Information
Table 106. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 107. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. ProQR Business Overview
Table 109. ProQR Recent Developments
Table 110. Exicure Basic Information
Table 111. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 112. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Exicure Business Overview
Table 114. Exicure Recent Developments
Table 115. Secarna Basic Information
Table 116. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 117. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Secarna Business Overview
Table 119. Secarna Recent Developments
Table 120. AstraZeneca Basic Information
Table 121. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 122. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. AstraZeneca Business Overview
Table 124. AstraZeneca Recent Developments
Table 125. The WhiteOak Group, Inc. Basic Information
Table 126. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 127. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. The WhiteOak Group, Inc. Business Overview
Table 129. The WhiteOak Group, Inc. Recent Developments
Table 130. Dicerna Basic Information
Table 131. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 132. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Dicerna Business Overview
Table 134. Dicerna Recent Developments
Table 135. Silence Basic Information
Table 136. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 137. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Silence Business Overview
Table 139. Silence Recent Developments
Table 140. Arrowhead Basic Information
Table 141. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 142. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Arrowhead Business Overview
Table 144. Arrowhead Recent Developments
Table 145. Miragen Therapeutics Basic Information
Table 146. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 147. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. Miragen Therapeutics Business Overview
Table 149. Miragen Therapeutics Recent Developments
Table 150. Genzyme Basic Information
Table 151. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 152. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 153. Genzyme Business Overview
Table 154. Genzyme Recent Developments
Table 155. Quark Pharmaceuticals Basic Information
Table 156. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 157. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 158. Quark Pharmaceuticals Business Overview
Table 159. Quark Pharmaceuticals Recent Developments
Table 160. Sylentis Basic Information
Table 161. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 162. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 163. Sylentis Business Overview
Table 164. Sylentis Recent Developments
Table 165. Avidity Biosciences Basic Information
Table 166. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 167. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 168. Avidity Biosciences Business Overview
Table 169. Avidity Biosciences Recent Developments
Table 170. Novo Nordisk Basic Information
Table 171. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 172. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 173. Novo Nordisk Business Overview
Table 174. Novo Nordisk Recent Developments
Table 175. Sirnaomics Basic Information
Table 176. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Overview
Table 177. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 178. Sirnaomics Business Overview
Table 179. Sirnaomics Recent Developments
Table 180. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Region (2026-2035) & (K MT)
Table 181. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Region (2026-2035) & (M USD)
Table 182. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 183. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 184. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 185. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 186. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Region (2026-2035) & (K MT)
Table 187. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Region (2026-2035) & (M USD)
Table 188. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 189. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 190. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Country (2026-2035) & (Units)
Table 191. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 192. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Type (2026-2035) & (K MT)
Table 193. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Type (2026-2035) & (M USD)
Table 194. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price Forecast by Type (2026-2035) & (USD/KG)
Table 195. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) Forecast by Application (2026-2035)
Table 196. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Antisense oligonucleotides (ASO) Drug and siRNA Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD), 2025-2035
Figure 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) (2020-2035)
Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Life Cycle
Figure 13. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Manufacturers in 2025
Figure 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Manufacturers in 2025
Figure 15. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue in 2025
Figure 18. Industry Chain Map of Antisense oligonucleotides (ASO) Drug and siRNA Drug
Figure 19. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market PEST Analysis
Figure 20. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type
Figure 27. Sales Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2020-2025)
Figure 28. Sales Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type in 2025
Figure 29. Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2020-2025)
Figure 30. Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application
Figure 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2020-2025)
Figure 34. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application in 2025
Figure 35. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application (2020-2025)
Figure 36. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application in 2025
Figure 37. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Growth Rate by Application (2020-2025)
Figure 38. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2020-2025)
Figure 39. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025)
Figure 40. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country in 2024
Figure 43. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country in 2024
Figure 45. U.S. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country in 2024
Figure 53. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country in 2024
Figure 55. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region in 2024
Figure 67. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region in 2024
Figure 68. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (K MT)
Figure 79. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country in 2024
Figure 80. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (M USD)
Figure 81. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country in 2024
Figure 82. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region in 2024
Figure 92. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Market Share by Region (2020-2025)
Figure 103. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) Growth Rate (2020-2025)
Figure 106. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Type (2026-2035)
Figure 111. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Application (2026-2035)
Figure 112. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Antisense oligonucleotides (ASO) Drug and siRNA Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD), 2025-2035
Figure 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) (2020-2035)
Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Life Cycle
Figure 13. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Manufacturers in 2025
Figure 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Manufacturers in 2025
Figure 15. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue in 2025
Figure 18. Industry Chain Map of Antisense oligonucleotides (ASO) Drug and siRNA Drug
Figure 19. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market PEST Analysis
Figure 20. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type
Figure 27. Sales Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2020-2025)
Figure 28. Sales Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type in 2025
Figure 29. Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2020-2025)
Figure 30. Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application
Figure 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2020-2025)
Figure 34. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application in 2025
Figure 35. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application (2020-2025)
Figure 36. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application in 2025
Figure 37. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Growth Rate by Application (2020-2025)
Figure 38. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2020-2025)
Figure 39. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025)
Figure 40. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country in 2024
Figure 43. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country in 2024
Figure 45. U.S. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country in 2024
Figure 53. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country in 2024
Figure 55. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region in 2024
Figure 67. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region in 2024
Figure 68. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (K MT)
Figure 79. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country in 2024
Figure 80. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (M USD)
Figure 81. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country in 2024
Figure 82. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region in 2024
Figure 92. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Market Share by Region (2020-2025)
Figure 103. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) Growth Rate (2020-2025)
Figure 106. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Type (2026-2035)
Figure 111. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Forecast by Application (2026-2035)
Figure 112. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Application (2026-2035)
